Literature DB >> 9029111

Differential responses to challenge with live and dead Mycobacterium bovis Bacillus Calmette-Guérin.

M A Chambers1, B G Marshall, A Wangoo, A Bune, H T Cook, R J Shaw, D B Young.   

Abstract

Bacillus Calmette-Guérin (BCG) vaccination has been shown to protect against challenge with virulent Mycobacterium tuberculosis in a range of experimental animal models: in each case, protective efficacy requires vaccination with live bacteria. With the goal of moving to a new generation of safer, nonliving vaccines, efforts have been made to identify the factors that determine the efficacy of live vaccination. We show that injection of live, but not dead, BCG induces localized swelling in the mouse footpad model. Live and dead bacteria induce similar responses during the first week after vaccination as determined by immunohistochemical analysis of the site of injection and of the draining lymph node. The subsequent differential response is characterized by migration of acid-fast bacilli to the draining lymph node in the case of the live vaccine. This is accompanied by an increase in mononuclear cells in the lymph node and by expression of inducible nitric oxide synthase (iNOS) both in the lymph node and at the site of injection. The ability of the bacteria to migrate to the lymph node may be an important element in the efficacy of live BCG vaccination.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9029111

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Immunity to Chlamydia trachomatis mouse pneumonitis induced by vaccination with live organisms correlates with early granulocyte-macrophage colony-stimulating factor and interleukin-12 production and with dendritic cell-like maturation.

Authors:  D Zhang; X Yang; H Lu; G Zhong; R C Brunham
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  Production of tumor necrosis factor and nitric oxide by macrophages infected with live and dead mycobacteria and their suppression by an interleukin-10-secreting recombinant.

Authors:  B G Marshall; M A Chambers; A Wangoo; R J Shaw; D B Young
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

3.  Stimulation of phagocytic activity of alveolar macrophages toward artificial microspheres by infection with mycobacteria.

Authors:  Keiji Hirota; Keishiro Tomoda; Hiroyuki Inagawa; Chie Kohchi; Gen-Ichiro Soma; Kimiko Makino; Hiroshi Terada
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

4.  Licensed Bacille Calmette-Guérin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation.

Authors:  Asimenia Angelidou; Maria-Giulia Conti; Joann Diray-Arce; Christine S Benn; Frank Shann; Mihai G Netea; Mark Liu; Lakshmi Prasad Potluri; Guzman Sanchez-Schmitz; Robert Husson; Al Ozonoff; Beate Kampmann; Simon Daniël van Haren; Ofer Levy
Journal:  Vaccine       Date:  2020-01-28       Impact factor: 4.169

5.  Cyclooxygenase-Derived Prostaglandin E2 Drives IL-1-Independent Mycobacterium bovis Bacille Calmette-Guérin-Triggered Skin Dendritic Cell Migration to Draining Lymph Node.

Authors:  Veronika Krmeská; Juliana Bernardi Aggio; Susanne Nylén; Pryscilla Fanini Wowk; Antonio Gigliotti Rothfuchs
Journal:  J Immunol       Date:  2022-05-06       Impact factor: 5.426

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.